## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

<del> </del>		·	<del></del>	
APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/696,487	10/29/2003	Malte Buchholz	21460 US	7548
151 7590 10/31/2007 HOFFMANN-LA ROCHE INC.			EXAMINER	
PATENT LAV	DEPARTMENT	·	UNGAR, SUSAN NMN	
340 KINGSLAND STREET NUTLEY, NJ 07110			ART UNIT	PAPER NUMBER
•			1642	
			NAME DE L'ARCE	2511752717025
			MAIL DATE	DELIVERY MODE
			10/31/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/696,487	BUCHHOLZ ET AL.	
Examiner	Art Unit	
Susan Ungar	1642	

--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --THE REPLY FILED 15 October 2007 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. 1. Me The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods: a) The period for reply expires <u>3</u> months from the mailing date of the final rejection. b) The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f). Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL 2. The Notice of Appeal was filed on \_\_\_\_. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a). **AMENDMENTS** 3. X The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below): (b) They raise the issue of new matter (see NOTE below); (c) They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) They present additional claims without canceling a corresponding number of finally rejected claims. NOTE: See Continuation Sheet. (See 37 CFR 1.116 and 41.33(a)). 4. The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324). 5. Applicant's reply has overcome the following rejection(s): 6. Newly proposed or amended claim(s) \_\_\_\_ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 7. Tor purposes of appeal, the proposed amendment(s): a) will not be entered, or b) will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: None. Claim(s) objected to: None. Claim(s) rejected: 1-3. Claim(s) withdrawn from consideration: 4-12. AFFIDAVIT OR OTHER EVIDENCE 8. The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e). 9. 🗌 The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will <u>not</u> be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1). 10. The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached. REQUEST FOR RECONSIDERATION/OTHER 11. The request for reconsideration has been considered but does NOT place the application in condition for allowance because: See Continuation Sheet. 12. Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s). 13. Other: Susan Ungar

Primary Examiner Art Unit: 1642

## **Continuation Sheet (PTO-303)**

Application No. 10/696,487

Continuation of 3. NOTE: Claim 1 is now drawn to a mRNA capable of producing a cDNA, however, although an mRNA is involved in the process, it is not possible for a nRNA to produce a cDNA, thus additional search and consideration is required.. Further, in order to clarify the record, although it appears that Applicant is attempting to be responsive to Examiner's rejection drawn to RNA that is useful to produce a cDNA and Applicant actually argues that claim 1 has been amended to recite language drawn to "useful in producing the cDNA of SEQ ID NO:1", in point of fact, this is not what the claim as currently constituted claims. A review of the Office Action of July 11, 2007, page 3 reveals that Examiner's exact words were "Although the claim is now drawn to detecting an mRNA encoding a polypeptide comprising SEQ ID NO:2, the issue remains the same, that is, there is no teaching in either the specification or the art or record that any mRNA other than that which is useful to produce the cDNA consisting of SEQ ID NO:1 ..." there is no suggestion that the mRNA alone, as instantly claimed, would be capable of producing cDNA consisting of SEQ ID NO:1.

Further Claim 2 now recotes "approximately 15-fold to approximately 60-fold and recites specific hybridization conditions that must be considered and searched, claim 3 also now recites specific hybridization onditions and three fold greater levels of mRNA which must be considered and searched,

.Continuation of 11. does NOT place the application in condition for allowance because the arguments submitted are drawn to the claims as amended and since the amendment has not been entered, the arguments are moot..